~~SECURITIES~~UNITED STATESSECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Pursuant~~Date toof ~~Section 13~~Report ~~or 15~~(d)Date of ~~the Securities~~earliest ~~Exchange~~event ~~Act~~reported) ofMay 30, ~~1934~~2006

~~Date of Report: November 21~~CytoCore, ~~2003~~Inc. ~~(Date of earliest event reported)~~

~~APPLIED~~(Exact ~~MOLECULAR~~name ~~EVOLUTION,~~of ~~INC.~~ registrant as specified in charter)

(Exact name of registrant as specified in its charter)


Delaware	0-935	36-4296006

(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Delaware	000-31101	33-0374014
414 North Orleans Street, Suite 502, Chicago, Illinois	60610
(State or other jurisdiction	(Commission	(IRS Employer
(Address of principal executive offices)	(Zip Code)
of incorporation)	File Number)	Identification No.)

~~3520~~Registrant’s ~~Dunhill~~telephone ~~Street~~number, ~~San~~including ~~Diego,~~area ~~California~~code ~~92121~~(312) 222-9550

~~(Address~~Molecular ofDiagnostics, ~~principal executive offices) (Zip Code)~~Inc.

~~Registrant’s~~(Former ~~telephone~~name ~~number~~or former address, ~~including~~if ~~area~~changed ~~code: (858~~since last report.) ~~597-4990~~

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.
	Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
	ITEM 7 FINANCIAL STATEMENTS AND EXHIBITS.
	Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
SIGNATURE
	Item 9.01. Financial Statements and Exhibits
INDEX TO EXHIBITS
SIGNATURES
Certificate of Amendment to Certificate of Incorporation

~~ITEM 5~~Item 3.01. ~~OTHER~~Notice ~~EVENTS~~of ~~AND~~Delisting ~~REGULATION~~or FDFailure ~~DISCLOSURE.~~to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

~~Effective~~The ~~November 21,~~company ~~2003,~~received ~~Applied~~notice ~~Molecular~~from ~~Evolution~~the NASD, ~~Inc.~~with ~~(the “Company”)~~a ~~and~~notification ~~EquiServe~~date ~~Trust~~of ~~Company~~May 30, ~~N.A. (“EquiServe”)~~2006, ~~amended~~that ~~(“Amendment~~the ~~No. 2”)~~company ~~the~~was ~~Rights~~delinquent ~~Agreement~~in ~~dated~~filing asits ofQuarterly ~~May 10,~~Report ~~2001~~on ~~between~~Form 10-QSB for the ~~Company~~quarter ~~and~~ended March ~~EquiServe~~31, as2006. ~~Rights~~As ~~Agent~~such, asthe ~~amended~~company bywas ~~Amendment~~not ~~No. 1~~current ~~dated~~in asits ofreporting ~~November~~obligations and not in compliance 4with NASD Rule 6530, ~~2002~~which ~~(the~~rule ~~“Rights~~requires ~~Agreement”).~~in ~~The~~part ~~following~~that ~~paragraphs~~an ~~summarize~~issuer file reports with the Securities ~~principal~~and ~~amendments~~Exchange Commission and be current in its reporting obligations (subject to ~~the~~a ~~Rights~~30 ~~Agreement~~or 60 day grace period, as ~~effectuated~~applicable). byThe ~~Amendment~~company ~~No.~~was given a 30-day grace period, until June 2.23, 2006, to ~~Capitalized~~regain ~~terms~~compliance. ~~not~~A ~~defined~~fifth ~~herein~~character ~~shall~~“E” ~~have~~was appended to the ~~meanings~~trading assymbol ~~set~~for ~~forth~~the incompany on the first business day after the ~~Rights~~delinquency ~~Agreement~~notification appeared on the Daily List.

1. The ~~definition~~company offiled ~~Acquiring~~its ~~Person~~Quarterly ~~was~~Report ~~revised~~on toForm ~~exclude~~10-QSB ~~Eli~~for ~~Lilly~~the ~~and Company~~quarter ~~(“Lilly”),~~ended ~~Genesis Merger Sub~~March 31, ~~Inc.~~2006 ~~(“Merger Sub”) and any Affiliate or~~on ~~Associate thereof, as a result of (i)~~June ~~the approval~~9, ~~execution~~2006 and ~~delivery~~notified of the ~~Agreement~~NASD ~~and Plan~~ of ~~Merger~~such byfact. ~~and~~The ~~among~~fifth ~~Lilly,~~character ~~Merger Sub and the Company dated as of November 21, 2003 (the~~ “~~Merger Agreement~~E”), ~~(ii) the~~was ~~approval, execution~~subsequently ~~and delivery of the Voting and Support Agreements dated as of~~removed ~~November 21, 2003 by and between Lilly and certain stockholders of the Company parties thereto, as amended~~ from ~~time to time (~~the ~~“Voting~~trading ~~and~~symbol ~~Support Agreements”),~~for ~~(iii)~~ the ~~acquisition~~company ofon ~~the shares of Common Stock pursuant to the Merger (as defined in the Merger Agreement), (iv) the consummation of any of the transactions contemplated by the Merger Agreement~~ or ~~the~~about ~~Voting and Support Agreements, or (v)~~June ~~the public announcement of any of the foregoing (each such event~~13, ~~an “Exempt Event”)~~2006.

2.Item ~~The~~5.03. ~~definitions~~Amendments ~~of Distribution Date and Stock Acquisition Date were revised~~ to ~~provide~~Articles ~~that~~of inIncorporation ~~no event shall a Distribution Date~~ or ~~Stock Acquisition~~Bylaws; ~~Date~~Change bein ~~deemed~~Fiscal ~~to occur as a result of an Exempt Event.~~Year

~~3. Sections 11(a)~~The ~~and~~company ~~13(~~filed a) ~~were~~Certificate ~~revised~~of Amendment to ~~provide~~its ~~that~~Certificate ~~such~~of ~~sections~~Incorporation (as amended ~~would~~to ~~not~~date) ~~apply~~with asthe aSecretary ~~result~~of State of anthe ~~Exempt~~State ~~Event~~of Delaware on June 22, 2006 to change the name of the company from Molecular Diagnostics, Inc. to CytoCore, Inc. Such amendment was approved by stockholders at the company’s annual meeting held on June 16, 2006 and became effective upon filing.

4.Item ~~Section 36~~9.01. ~~was~~Financial ~~added~~Statements ~~to provide that the Rights Plan would terminate~~ and ~~the Rights would expire immediately prior to the Effective Time (as defined~~Exhibits ~~in the Merger Agreement).~~

~~ITEM 7 FINANCIAL STATEMENTS AND EXHIBITS~~ (d) Exhibits.

(C)		Exhibits.
4.1		Rights Agreement dated as of May 10, 2001 between Applied Molecular Evolution, Inc. and EquiServe Trust Company, N.A. which includes as Exhibit B the form of Rights Certificate. Pursuant to the Rights Agreement, Rights Certificates will not be mailed until the earlier of (i) a public announcement that a person or a group of affiliated or associated persons has acquired beneficial ownership of securities representing 15% or more of the outstanding common stock or (ii) ten days after a person or a group of affiliated or associated persons has commenced or announced an intent to commence a tender offer or exchange offer which, upon consummation thereof, would cause such person or group to own beneficially securities representing 15% or more of the outstanding common

3.1 Certificate of Amendment to Certificate of Incorporation (as amended to date), as filed on June 22, 2006

-2-

		stock (filed as Exhibit 4.1 to the Company’s Registration Statement on Form 8-A (File No. 000-31101) and incorporated herein by reference).
4.2		Amendment No. 1 to Rights Agreement dated as of November 4, 2002 between Applied Molecular Evolution, Inc. and EquiServe Trust Company, N.A., as Rights Agent (filed as Exhibit 4.2 to Amendment No. 1 to the Company’s Registration Statement on Form 8-A (File No. 000-31101) and incorporated herein by reference).
4.3		Amendment No. 2 to Rights Agreement dated as of November 21, 2003 between Applied Molecular Evolution, Inc. and EquiServe Trust Company, N.A., as Rights Agent (filed as Exhibit 4.3 to Amendment No. 2 to the Company’s Registration Statement on Form 8-A (File No. 000-31101) and incorporated herein by reference).

SIGNATURES

-3-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 21, 2003


	Molecular Diagnostics, Inc.
Dated: June 28, 2006	By:	/s/ David Weissberg, M.D.
		David Weissberg, M.D.
		Chairman and Chief Executive Officer

APPLIED MOLECULAR EVOLUTION, INC. By /s/ LAWRENCE E. BLOCH Lawrence E. Bloch, M.D., J.D. Chief Financial Officer and Secretary

-4-

INDEX TO EXHIBITS

Exhibit
Number		Exhibit
4.1		Rights Agreement dated as of May 10, 2001 between Applied Molecular Evolution, Inc. and EquiServe Trust Company, N.A. which includes as Exhibit B the form of Rights Certificate. Pursuant to the Rights Agreement, Rights Certificates will not be mailed until the earlier of (i) a public announcement that a person or a group of affiliated or associated persons has acquired beneficial ownership of securities representing 15% or more of the outstanding common stock or (ii) ten days after a person or a group of affiliated or associated persons has commenced or announced an intent to commence a tender offer or exchange offer which, upon consummation thereof, would cause such person or group to own beneficially securities representing 15% or more of the outstanding common stock (filed as Exhibit 4.1 to the Company’s Registration Statement on Form 8-A (File No. 000-31101) and incorporated herein by reference).
4.2		Amendment No. 1 to Rights Agreement dated as of November 4, 2002 between Applied Molecular Evolution, Inc. and EquiServe Trust Company, N.A., as Rights Agent (filed as Exhibit 4.2 to Amendment No. 1 to the Company’s Registration Statement on Form 8-A (File No. 000-31101) and incorporated herein by reference).
4.3		Amendment No. 2 to Rights Agreement dated as of November 21, 2003 between Applied Molecular Evolution, Inc. and EquiServe Trust Company, N.A., as Rights Agent (filed as Exhibit 4.3 to Amendment No. 2 to the Company’s Registration Statement on Form 8-A (File No. 000-31101) and incorporated herein by reference).

-5-

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Filing Compare · CytoCore, Inc.